GBM22 GBM Model

Dive into brain cancer research with GBM22, a Patient-Derived Xenograft (PDX) model that closely mirrors the disease. GBM22 offers an ideal platform for exploring treatment options and mechanisms. PDX models like GBM22 are indispensable for preclinical drug discovery due to their ability to recapitulate patient-specific tumor characteristics. Researchers can use GBM22 to test the effectiveness of various drug candidates and tailor treatment strategies to individual patients. By leveraging GBM22, you can accelerate the development of targeted therapies and improve outcomes for brain cancer patients.

Model Details

Cancer Location: Intracranial
Cancer Type: Brain Cancer
Model Name: GBM22
Mouse Strain: Nu/Nu
Treatment Data Available: Chemotherapy (Temozolomide, Temodar, Lomustine)
WES: Yes
RNAseq: Yes
Methylation: Yes
PDX Treatment: Yes
Patient Treatment History: Yes

GBM22 Survival

Survival of orthotopic intracranial implanted  GBM22 in Nu/Nu mice  (n=5

Request Additional GBM Model Data

Contact Us

Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our
expert staff today to get started.

Skip to content